GSK paid $85 million to
* $56.8 mln for speaking engagements and advice
* $28.5 mln for
LONDON, March 31 (Reuters) - GlaxoSmithKline (GSK.L) said on Thursday it paid $85.3 million to U.S. doctors and researchers in 2010 for a variety of services, including speaking fees, expert advice and work on clinical trials of its medicines.
The disclosure is the latest example of Big Pharma bowing to pressure for greater transparency, following concerns in the
GSK has previously given details on payments to speakers, but not clinical trials.
In 2010, a total of 5,331
Payments to
Speaking engagements, in which doctors are paid by drugmakers to discuss their medicines with groups of other physicians, have been among the most controversial industry marketing practices.
By law, companies are forbidden to promote their drugs for uses not cleared by the U.S. Food and Drug Administration. But some companies allegedly have greatly boosted prescriptions for their drugs by allowing or encouraging paid speakers to discuss such "off-label" use of their products. (Reporting by Ben Hirschler; Editing by Will Waterman)